De-cellularized Amniotic Fluid for Joint Cartilage Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for joint pain, injury, and degeneration are limited in effectiveness, primarily relying on surgical procedures and palliative methods such as injections of hyaluronic acid, which do not fully address chronic issues or promote significant healing and mobility restoration.
Innovation Solution
A sterile de-cellularized human amniotic fluid (D-HAF) formulation containing over 300 growth factors is developed, administered via injection or other methods to treat joint conditions, promote healing, reduce inflammation, and enhance joint mobility, potentially combined with additional therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical procedures and palliative injections (hyaluronic acid, steroids) are used for joint treatment, then pain relief and mobility improvement are achieved, but healing promotion and cartilage regeneration are insufficient
Solution Approach 1:
The patent extracts and utilizes over 300 specific growth factors naturally present in human amniotic fluid, isolating the therapeutic components responsible for tissue regeneration and healing while removing non-essential elements. This extraction principle transforms the entire amniotic fluid into a targeted therapeutic formulation rich in healing-promoting growth factors.
2Duration of action of moving object
If conventional treatments (steroids, anesthetics, hyaluronic acid) are administered, then temporary symptom relief is achieved, but long-term healing and structural repair are limited
Solution Approach 1:
The patent fundamentally changes the therapeutic parameter from temporary symptom management to long-term structural healing by introducing growth factors that actively promote tissue regeneration. This parameter change transforms the treatment outcome from palliative relief to curative repair, extending both duration and reliability of therapeutic effect.
3Object-affected harmful factors
If de-cellularization and sterilization processes are applied to amniotic fluid, then safety and sterility are ensured, but growth factor retention must be maintained
Solution Approach 1:
The patent applies de-cellularization and sterilization processes in advance of therapeutic administration, preparing the amniotic fluid formulation beforehand to ensure safety and sterility while preserving growth factor activity. This preliminary action allows the product to be stored and administered without compromising either safety or therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The D-HAF formulation effectively reduces pain, promotes healing, and increases joint mobility, demonstrating significant improvement in conditions such as osteoarthritis and other joint-related disorders by regenerating cartilage and soft tissue repair.
Implementation Method 1
D-HAF contains over 300 human growth factors
Data Source
AI summary
A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stemcells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on the severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft.